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ABSTRACT 
 
Aims: Monoclonal antibodies against tumor-related molecules are therapeutic agents for cancers. 
Promising results support the use of monoclonal antibodies in several cancers such as lung and 
breast cancer. However, using monoclonal antibodies as therapeutic agents to treat hepatocellular 
carcinoma (HCC), a major type of liver cancer, is still at the beginning. We have previously 
generated a monoclonal antibody against cadherin-17 (CDH17), named Lic5. This antibody has 
proven anti-tumor and cisplatin-sensitizing effect in HCC using a subcutaneous tumor xenograft 
mouse model.  
Original Research Article 
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Study Design and Methodology: To further consolidate our previous finding, we tested the effect 
of Lic5 alone or in combination with cisplatin or epirubicin on tumor growth inhibition and animal 
survival using a more advanced orthotopic tumor xenograft model.  
Results: Single Lic5, cisplatin and epirubicin treatment inhibited growth of cultured HCC cells using 
cell proliferation assay, while more significant reductions were observed when cisplatin or epirubicin 
was used together with Lic5. Similar trends of growth inhibition were observed when the same 
experimental grouping was applied to treat orthotopic tumor-bearing nude mice. Treatment of Lic5 
enhanced survivals of orthotopic tumor-bearing nude mice when compared to the control group. 
Among all experimental groups, combined Lic5 and epirubicin group yielded the best survival. For 
next phase antibody humanization, we also identified the complementarity determining regions 
(CDRs) on variable regions on the light and heavy chain of Lic5.  
Conclusion: Together, we have validated the preclinical use of Lic5 in an orthotopic HCC 
xenograft model. Our successful identification of CDRs constitutes the first step in synthesizing 
humanized Lic5. 
 
 
Keywords: Cadherin-17; Lic5; cisplatin; epirubicin; survival. 
 
1. INTRODUCTION 
 
Global incidence of liver cancer ranks top among 
various gastrointestinal cancers. More than half a 
million new cases appear each year, concordant 
with an approximately equal number of deaths 
annually. Hepatocellular carcinoma (HCC) is a 
major type of liver cancer, contributing up to 
more than 80% of total cases. Resectable 
patients can be treated by frontline tumor 
resection, while such curative treatment does not 
benefit advanced stage patients presented with 
multi-nodal or even metastatic tumors. Unlike a 
number of solid tumors that can be treated quite 
effectively using chemotherapeutic drugs, HCC is 
rather resistant to traditional chemotherapeutics 
including cisplatin and epirubicin. Although 
molecular targeting drug Sorafenib, a multi-
kinase inhibitor, is clinically approved for treating 
unresectable, advanced stage patients, its drug 
efficacy is modest. To improve this clinical 
situation and to offer new treatment options for 
patients not amendable for current therapies, it is 
our longstanding efforts to research for HCC-
related molecules for therapeutic targeting.  
 
Cadherin-17 (CDH17) is an oncofetal molecule 
first identified by our group to be overexpressed 
in more than half of the HCC cases [1]. Later 
studies further demonstrated the clinical 
correlation of CDH17 overexpression with 
advanced HCC condition such as tumor invasion 
and late stage tumor [2,3]. We deciphered its 
tumorigenic mechanism by showing its 
intersection with a frequently deregulated Wnt/β-
catenin pathway in HCC that leads to the 
formation of a novel CDH17/β-catenin axis. 
Activation of this axis stimulates the expression 
of several tumorigenic molecules including cell 
cycle regulator cyclin D1 [3,4]. Besides, we also 
unraveled its tumorigenic effects in cultured HCC 
cells and their derived tumor xenografts in nude 
mice using a series of functional assays and 
animal models. These prior studies have put 
forth the concept of targeting CDH17 for therapy. 
Exogenous suppression of CDH17 using RNA 
interference or our in-house generated 
monoclonal antibody against CDH17 (Lic5) 
significantly reduced growth of subcutaneous 
HCC tumors [3,5]. Enhanced suppression on 
growth of subcutaneous tumors was observed 
when we combined the use of Lic5 with a 
conventional chemotherapeutic cisplatin [5]. Our 
prior results have undoubtedly described the 
tumor-suppressing effect of Lic5 and its cisplatin-
sensitizing effect.  
 
Along this research line, this study performed in-
depth analyses on the tumor-suppressing and 
chemosensitizing effects of Lic5 on a more 
clinically relevant orthotopic HCC xenograft 
model. In addition, we also exploited the 
complementarity determining regions (CDRs) on 
the variable regions of heavy chain and light 
chain of Lic5, for which this information is 
essential for reducing the immunogenicity of 
mouse antibody through antibody humanization 
before clinical application. In all, this study 
consolidates the preclinical usefulness of Lic5 on 
HCC by a more advanced animal model. The 
derived CDR information can lay as a foundation 
for next phase production of humanized Lic5 for 
clinical use. 
               
2. MATERIALS AND METHODS 
 
2.1 Human HCC Cell Lines 
 
Human HCC cell lines MHCC97-L (97L) and 
PLC/PRF/5 (PLC) were used as before [6,7]. 
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Both cell lines were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Life 
Technologies, Grand Island, NY, USA) 
supplemented with 10% heat-inactivated fetal 
bovine serum (FBS) (Life Technologies), 100 
units/ml penicillin and streptomycin (Life 
Technologies). Cultured cells were maintained in 
a humidified atmosphere at 37°C with 5% carbon 
dioxide.  
 
2.2 Production and Characterization of 
Lic5, an in-house Monoclonal 
Antibody against CDH17 
 
An in-house hybridoma cell line secreting Lic5 
was generated as described [5]. Hybridoma cells 
were maintained in DMEM supplemented with 
10% FBS and 100 units/ml penicillin and 
streptomycin. To collect Lic5, hybridoma cells 
were cultured in serum-free hybridoma-SFM (Life 
Technologies) for 6 days. Cultured supernatant 
was collected and purified using Protein G 
column (Life Technologies). Concentration of the 
purified Lic5 was estimated using RC DC Protein 
Assay (Bio-Rad, Hercules, CA, USA). Purity of 
Lic5 was assessed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) 
under reducing condition, followed by Coomassie 
Blue staining. Immunoreactivity and specificity of 
Lic5 was confirmed by western blot using 97L 
cell lysate and by immunohistochemistry using 
paraffin-embedded human HCC tissue. The use 
of clinical specimen for research was approved 
by the Institutional Review Board of The 
University of Hong Kong/Hospital Authority Hong 
Kong West Cluster (HKU/HA HKW IRB). The 
procedures for SDS-PAGE, Coomassie Blue 
staining and western blot were routinely 
performed [8-10], while the method for 
immunohistochemistry was described below.              
 
2.3 In vitro Cell Proliferation Assay 
 
Pre-determined number of 97L and PLC cells 
was seeded onto 96-well culture plates for 1 day 
before treatment with Lic5 and/or 
chemotherapeutic drugs, cisplatin 
(Pharmachemie BV, Netherlands) and epirubicin 
(Pfizer, New York, NY, USA). Cells were 
subjected to the following treatments for 2 days: 
(1) 150 µg/ml Lic5; (2) 0.156 µg/ml and 0.625 
µg/ml cisplatin for 97L and PLC cells, 
respectively; (3) 0.04 µg/ml and 0.01 µg/ml 
epirubicin for 97L and PLC cells, respectively; (4) 
combined treatment of Lic5 and cisplatin; (5) 
combined treatment of Lic5 and epirubicin; (6) 
150 µg/ml mouse IgG (Sigma-Aldrich, St Louis, 
MO, USA) as a control for Lic5. After treatment, 
proliferation of treated cells was measured using 
Cell Proliferation Kit I (Roche, Indianapolis, IN, 
USA) and as described [10]. In brief, MTT 
reagent was incubated with the treated cells for 4 
hours. Colorimetric signals were then measured 
after addition of 10% SDS. Independent cell 
proliferation MTT assays were performed at least 
twice for result confirmation.     
 
2.4 Orthotopic Tumor Xenograft Model 
 
Male nude mice were obtained from Laboratory 
Animal Unit of The University of Hong Kong, 
Hong Kong. Animals were housed in individually 
ventilated cages under a 12-hour light/12-hour 
dark cycle and with free access to autoclaved 
water and chow. Animal experiments performed 
in this study were approved by the Committee on 
the Use of Live Animals in Teaching and 
Research (CULATR) of our institute. To allow in 
vivo viewing of the growing orthotopic liver 
tumors, previously established luciferase-labelled 
97L cell line was used [11]. 5 x 106 luciferase-
labelled 97L cells were injected subcutaneously 
into nude mice to allow the growth of the 
subcutaneous tumors. These subcutaneous 
tumors were harvested when their sizes reached 
200-300 mm3 and used as tumor seeds to 
establish orthotopic liver tumors in a separate 
group of nude mice following the standard 
procedure [11]. Five days after orthotopic tumor 
implantation, mice received different treatments 
as following via intraperitoneal administration 3 
times/week for 3 weeks (10-11 mice in each 
group): (1) 6 mg/kg Lic5; (2) 1 mg/kg cisplatin;               
(3) 1 mg/kg epirubicin; (4) combined treatment of 
Lic5 and cisplatin; (5) combined treatment of Lic5 
and epirubicin; (6) 6 mg/kg mouse IgG as Lic5 
control. Every week after treatment, orthotopic 
tumor growth and metastasis were monitored by 
live imaging in an IVIS 100 In Vivo Imaging 
System (Perkin Elmer, Waltham, MA, USA) after 
intraperitoneal injection of 150 mg/kg potassium 
luciferin (Gold Biotechnology, St Louis, MO, 
USA). For each measurement, a net photon 
count was obtained for each tumor. At the end of 
the experiment, orthotopic tumors were collected 
and subjected for formalin fixation and paraffin 
embedding.  
 
2.5 Animal Survival Study 
 
Orthotopic liver tumors were established as 
above using 97L cells. Orthotopic tumor-bearing 
mice received the following treatments 
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intraperitoneally 3 times/week for 3 weeks (11-15 
mice in each group): (1) 8 mg/kg Lic5; (2) 1 
mg/kg cisplatin; (3) 1 mg/kg epirubicin; (4) 
combined treatment of Lic5 and cisplatin; (5) 
combined treatment of Lic5 and epirubicin; (6) 8 
mg/kg mouse IgG as Lic5 control. Animal survival 
was continuously monitored till 6 weeks after 
treatment.  
 
2.6 Immunohistochemistry 
 
Immunohistochemistry was performed on 
paraffin-embedded orthotopic tumor xenografts 
and human HCC specimen as described [10,12]. 
In brief, 6 µm sections were prepared for 
deparaffinization and rehydration. After antigen 
retrieval and hydrogen peroxide treatment, 
sections were blocked with 3% bovine serum 
albumin before staining with mouse monoclonal 
antibody against β-catenin (1:200; BD 
Biosciences, San Jose, CA, USA) and Lic5 
(0.0625 µg/ml) overnight at 4°C. Signals were 
detected using EnVision+ System-HRP Labelled 
Polymer Anti-mouse (Dako, Carpinteria, CA, 
USA) and visualized using Liquid DAB+ 
Substrate Chromogen System (Dako). 
Counterstaining was performed using 
hematoxylin. Images were captured using 
DXM1200F digital camera (Nikon, Melville, NY, 
USA).  
 
2.7 Cloning of Variable Regions of Lic5 
 
Total RNA was extracted from Lic5-secreting 
hybridoma cells using TRIzol reagent (Life 
Technologies) and converted to cDNA using 
SuperScript III First-Strand Synthesis System 
(Life Technologies). Variable region cDNA 
fragments from heavy chain and light chain of 
Lic5 were amplified using Ig-Primer Set 
(Novagen, Germany) and Platinum Taq DNA 
Polymerase High Fidelity (Life Technologies). 
Variable region of light chain was amplified by 
the 5’ variable region primer (5’-
ATGGAGACAGACACACTCCTGCTAT-3’) and 3’ 
primer on the constant region, while variable 
region of heavy chain was obtained by the 5’ 
variable region primer (5’-
ATGAACTTYGGGYTSAGMTTGRTTT-3’, in 
which Y=C/T, S=C/G, M=A/C, and R=A/G) and 3’ 
primer on the constant region. PCR products 
after resolving on a 1.5% agarose gel were 
purified and sequenced (BGI, Hong Kong).   
 
2.8 Identification of CDR of Lic5  
 
The nucleotide sequences of variable region of 
heavy chain and light chain of Lic5 were used to 
derive the amino acid sequences, which were 
then numbered according to Kabat numbering 
scheme. CDR was identified according to Kabat 
definition (www.bioinf.org.uk).     
 
2.9 Statistical Analyses 
 
Statistical analyses were performed using SPSS 
version 19 (SPSS Inc., Chicago, IL, USA). Data 
presented in bar chart are expressed as mean ± 
SD/SEM. Student’s t-test was used to calculate 
the significance of difference between treatment 
groups and control group in both cell proliferation 
MTT assay and animal tumor xenograft 
experiments. Kaplan-Meier method was 
employed for survival analyses, while the 
differences in survival were calculated using log-
rank test. A p-value of less than 0.05 was 
considered statistically significant.    
 
3. RESULTS 
 
3.1 Establishment of a Pipeline for 
Purifying Large Quantity of Lic5 from 
Hybridoma Cell Culture Supernatant 
 
To obtain Lic5 with high purity and quantity for in 
vitro and in vivo experiments, we cultured Lic5-
secreting hybridoma cells in serum-free medium. 
Our established pipeline for purifying Lic5 
achieved a good antibody purity and yield. 
Coomassie Blue staining result revealed two 
prominent bands of about 55 and 27 kDa 
corresponding to the heavy and light chain of 
antibody on Day 6 culture supernatant, while 
these bands were not observed on Day 1 culture 
supernatant. With the presence of detectable 
level of antibody, culture supernatant collected 
on Day 6 was subjected to Protein G affinity 
chromatography for antibody purification. 
Successful binding of antibody onto the Protein 
G column was confirmed when we failed to 
detect the presence of antibody in the flow-
through after loading Day 6 culture supernatant 
onto the column. Antibody elution performed on 
different fractions (eluent E1 to E4) revealed the 
second and third elution fraction contained most 
abundant antibody. The two stained bands 
corresponding to the heavy and light chain of the 
antibody are the predominant bands detected on 
the protein gel, implicating our antibody purity 
with more than 90% (Fig. 1A). Using our antibody 
purification pipeline, we managed to collect a 
favorable antibody amount of 23.88±6.96 mg 
Lic5 from each liter of culture supernatant 
collected on Day 6.  
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The purified Lic5 demonstrated high 
immunoreactivity against CDH17. A single       
band of about 120 kDa corresponding to the 
apparent molecular weight of CDH17 was 
detected in CDH17-expressing 97L cells when 
we used Lic5 as a primary antibody for western 
blot (Fig. 1B). When Lic5 was used for 
immunohistochemistry to detect CDH17 in 
human HCC tissue, discrete stains appeared at 
the cell membrane and cytoplasm (Fig. 1C). The 
immunohistochemical stains generated by using 
Lic5 in this study was similar to the previous 
report with the use of a commercial antibody 
against CDH17 for immunohistochemistry            
[1]. 
 
3.2 Survival Benefit of Lic5 
 
Our previous report has demonstrated the 
chemosensitizing effect of Lic5 towards a 
commonly used chemotherapeutic drug cisplatin 
in a subcutaneous tumor xenograft model                 
[5]. To consolidate our earlier finding, we 
examined the chemosensitizing effect of Lic5 
towards another chemotherapeutic drug 
epirubicin, which is also commonly used in              
HCC. Besides, we performed the drug             
testing with or without Lic5 in a more            
clinically relevant orthotopic tumor xenograft                
model. 
  
Before treating orthotopic tumor-bearing mice 
with the purified Lic5, we first examined the anti-
tumor effect of Lic5 alone or combined with 
cisplatin or epirubicin in cultured HCC cell lines in 
vitro using cell proliferation MTT assay (Fig. 2A). 
When we performed cell proliferation assay on 
cultured 97L cells, treatment with cisplatin and 
epirubicin for 2 days resulted in 31.6% and 
21.9% growth inhibition, respectively. 
Combination with Lic5 further enhanced the 
growth inhibition effect by 1.74-fold for cisplatin 
and 1.98-fold for epirubicin, which led to a growth 
inhibition of 55.1% and 43.3%, respectively             
(Fig. 2A, left panel). Similar growth inhibition was 
observed in cultured PLC cells, in which 
treatment with cisplatin resulted in 37.6% growth 
inhibition and combined treatment with Lic5 
further increased the growth inhibition by 1.73-
fold (65.2%). Unlike the significant growth 
inhibition of epirubicin on cultured 97L cells, this 
drug only inhibited growth of cultured PLC cells 
by 8.1%. Likewise, its combination with Lic5 
enhanced the growth inhibition by 4.62-fold and 
led to a significant inhibition of 37.4% (Fig. 2, 
right panel).  
 
 
 
Fig. 1. Purification of Lic5 and its characterization 
Lic5 was purified using Protein G affinity chromatography from culture supernatant of Lic5-secreting hybridoma 
cell line. (A) As shown on the Coomassie Blue-stained gel, culture supernatant (culture S/N) from Day 6 (D6) 
contained higher antibody amount than Day 1 (D1). Two stained bands with sizes of about 55 kDa and 27 kDa 
corresponding to the heavy chain and light chain of antibody were visualized on the gel. No antibody was 
detected in the flow-through (FT) after we passed the Day 6 culture supernatant on the Protein G column. 
Antibody elution was performed on 4 fractions (E1 to E4). Most abundant antibody was eluted in fractions E2 and 
E3, which was collected and pooled. (B) Using purified Lic5 for western blot on 97L cell lysate, a single band 
corresponding to the apparent molecule weight of CDH17 was revealed. (C) Using purified Lic5 for 
immunohistochemistry on human HCC tissue, discrete stains corresponding to the membrane and cytoplasmic 
localizations of CDH17 were detected, for which this staining pattern corresponded well to our published report [1] 
  
 
 
Chan et al.; JALSI, 4(3): 1-10, 2016; Article no.JALSI.22188 
 
 
 
6 
 
 
 
Fig. 2. Chemosensitizing effect of Lic5 
(A) Single treatment of Lic5, cisplatin or epirubicin for 2 days inhibited the growth of 
cultured 97L and PLC cells when compared to the mouse IgG-treated cells in cell proliferation MTT assay. 
Further growth inhibition was observed when we treated the cultured cells under combined treatment of Lic5 with 
cisplatin or epirubicin. Bars represent mean ± SD. (B) Luciferase-labelled 97L cells were used to establish 
orthotopic tumor xenografts in nude mice. Single and combined treatments of Lic5 with or without 
chemotherapeutic drugs cisplatin and epirubicin were applied to these animals for 3 weeks. The data shown are 
net photon count relative to the control IgG group obtained 3 weeks after treatment. Single treatment yielded 
tumor growth inhibition, while further reduction on tumor growth was observed when Lic5 was combined with 
cisplatin or epirubicin. Bars represent mean + SEM. (C) Orthotopic tumor xenografts were established in nude 
mice using 97L cells. These animals were treated with single or combined treatment of Lic5 and epirubicin. 
Combined treatment of Lic5 and epirubicin led to most favorable survival as revealed in the Kaplan-Meier curve. 
A statistical significant difference in survivals was reached when we compared the combined treatment group 
with mouse IgG control group (p = 0.017). Abbreviations used: C, cisplatin; E, epirubicin. **, p < 0.05; ns, 
statistically not significant 
 
After confirming the chemosensitizing effect of 
Lic5 towards cisplatin and epirubicin treatment 
on cultured HCC cells by cell proliferation MTT 
assay, we examined whether similar growth 
inhibition was observed in an in vivo setting by 
animal tumor xenograft experiments. We used 
luciferase-labelled 97L cells to develop orthotopic 
tumor xenografts for treatments as this enables 
live monitoring of tumor growth. When compared 
to IgG control group, cisplatin treatment inhibited 
the xenograft growth by 48.6%. Such treatment 
when combined with Lic5 further augmented the 
xenograft growth inhibition by 1.64-fold to 79.6%. 
Despite such inhibition, the combined treatment 
data did not yield a statistical significant value 
when compared to control group (p = 0.08). For 
epirubicin, its combined treatment with Lic5 
manifested a further reduction of xenograft 
growth from 37.9% for single epirubicin treatment 
to 86.4% (i.e. 2.28-fold). However, such drop in 
xenograft growth still did not reach a statistical 
significant value (p = 0.07) (Fig. 2B). At the end 
of the experiment, we collected the orthotopic 
tumors for analyzing the expression and 
localization of β-catenin, which is known as a 
downstream molecule of CDH17 and is a key 
member of the Wnt signaling pathway. Both 
combined treatment of Lic5 with cisplatin or 
epirubicin reduced the overall expression and 
cytoplasmic localization of β-catenin when 
compared to single treatment of 
chemotherapeutic drugs (Supplementary Fig. 1). 
Such immunohistochemical results further 
strengthen the tumor-suppressing effect 
mediated by Lic5 via its action on altering the 
expression and localization of β-catenin. 
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As shown in Fig. 2B, a trend of tumor growth 
reduction was observed for every treatment 
group when compared to control group. We then 
compared the survival rate of orthotopic tumor-
bearing mice for each treatment group versus 
control group. The animal survival rate of Lic5 
group reached 63.6%, which was much higher 
than that of the control group (26.6%). Although 
the survival rate between control group and 
epirubicin group was similar (26.6% versus 25%), 
combined treatment of Lic5 and epirubicin led to 
the most significant increase in survival rate to 
81% among all experimental groups when 
compared to control group (p = 0.017) (Fig 2C). 
However, such significant difference in survival 
for cisplatin group and cisplatin with Lic5 group 
did not reach any statistical significant values 
when compared to control group (data not 
shown). Taken together, this set of animal 
experiments has demonstrated the 
chemosensitizing effect of Lic5 in particular for 
epirubicin on tumor growth inhibition and survival 
rate induction.   
 
3.3 Identification of CDR on Variable 
Regions of Lic5 
 
Each monoclonal antibody has its unique 
variable regions on heavy chain and light chain, 
for which each of them is composed of a 
sequence of amino acids that determines the 
antigen binding property of this antibody. To 
obtain the variable region sequences from heavy 
chain and light chain of Lic5, we amplified each 
variable region using discrete primer pairs (Fig. 3, 
left panel). After Sanger sequencing of the 
amplified products, the nucleotide sequences 
were translated into amino acid sequences by in 
silico method. Kabat numbering scheme and 
CDR definition were employed to identify the 
three CDRs on the variable regions of heavy 
chain and light chain of Lic5 using the deduced 
amino acid sequences (Fig. 3, right panel). 
 
4. DISCUSSION 
 
This study continues our previous study on 
testing the anti-tumor and chemosensitizing 
effect of Lic5 on HCC. Our previous study 
examined such properties of Lic5 in a 
subcutaneous tumor xenograft model [5], while 
this current study adopted the use of a more 
clinically relevant orthotopic tumor xenograft 
model. Although subcutaneous xenograft model 
is widely used for preclinical drug screening, the 
use of orthotopic xenograft model associates 
with added advantage by growing the tumor 
xenograft in the same environment as in the 
clinical situation. Therefore, orthotopic xenograft 
model is a more advanced animal model for 
preclinical drug testing, which can be used 
effectively for monitoring target site drug delivery, 
drug efficacy and pharmacokinetics [13]. Despite 
such advantage, establishment of orthotopic 
xenograft is more technically demanding due to 
the need to pre-label implanted tumor seeds for 
 
 
 
Fig. 3. Amino acid sequences of the variable regions of light chain and heavy chain of Lic5 
PCR followed by Sanger sequencing were used to obtain the variable region sequences of light chain and heavy 
chain of Lic5 from cDNA prepared from Lic5-secreting hybridoma cells (left panel). Based on the Kabat 
numbering scheme and CDR definition, the six CDRs on the two variable regions were identified and highlighted 
in different colors (right panel) 
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real-time monitoring of xenograft growth and the 
need for animal surgery for tumor seed 
implantation. Till now, it is still unsure whether 
tumor seed pre-labelling would introduce 
unpredicted factor that might interfere the drug 
efficacy assessment. Even though we observed 
a drop in tumor growth of the luciferase-labelled 
orthotopic tumors after Lic5 treatment, this 
growth inhibition did not reach a statistical 
significant difference when compared to the IgG 
treatment. This experimental result did not match 
well with our previous result showing a significant 
growth inhibition of non-labelled subcutaneous 
tumors after treating with Lic5 [5]. Similar result 
deviation was noticed when we compared the 
use of luciferase-labelled orthotopic tumors with 
non-labelled subcutaneous tumors under 
combined treatment of Lic5 with cisplatin. 
 
Our results have demonstrated the anti-tumor 
and chemosensitizing effects of Lic5 in treating 
HCC xenografts, implicating our in-house 
generated monoclonal antibody might be useful 
to treat other cancers apart from HCC. Lic5 was 
a monoclonal antibody produced in parallel with 
Lic3 by our team earlier using recombinant 
ectodomain 1-2 of CDH17 as an immunogen [3]. 
Since Lic5 targets the extracellular region of 
CDH17, it can bind to intact form or carboxyl-
terminal truncated form of CDH17 when used for 
therapeutic purpose. Therefore, it is obvious Lic5 
can be used to target other cancers with CDH17 
overexpression. In addition to HCC, a number of 
cancers are found overexpressing CDH17, which 
include gastric adenocarcinoma, esophageal 
adenocarcinoma, and colorectal cancers [4,14]. 
Among these cancer types, CDH17 
overexpression was present in majority of 
colorectal and esophageal adenocarcinoma 
cancers [15,16]. As such, these CDH17-
overexpressing cancers might also be 
susceptible to the action of Lic5. Several studies 
performing CDH17 suppression counteracted 
tumorigenesis as manifested by reduced growth 
of cultured cells or tumor xenografts after 
treatment [17,18]. Thus, targeting CDH17 to 
counteract tumorigenesis seems to work well in 
other cancers overexpressing CDH17 in addition 
to HCC. This opens up an opportunity of 
targeting CDH17 using Lic5 in other cancers for 
therapy.   
 
In this and our previous studies, we have 
reported targeting CDH17 using Lic5 inactivated 
CDH17/β-catenin axis by interfering with the 
expression and localization of the axis 
components such as β-catenin [5]. Except for 
one study on gastric cancer that demonstrated 
similar result [19], no other studies have yet 
reported this linkage between CDH17 and β-
catenin-associated network. Instead in another 
cancer type, CDH17 was bridged to integrin-
related pathway during colorectal tumorigenesis 
because of the intrinsic integrin-binding affinity    
of CDH17 [20,21]. CDH17 also affects two      
other tumorigenic pathways related to 
Ras/Raf/MEK/ERK and NFκB, such that its 
suppression inactivated these pathways in 
gastric cancer [22,23]. Given these observations, 
it remains to be determined whether Lic5 could 
also block these pathways as a mean to 
suppress tumorigenesis.  
 
Apart from testing the anti-tumor effects of Lic5, 
we also identified the three CDRs on each 
variable region on heavy and light chains of Lic5, 
for which these CDRs are responsible for 
determining antibody binding affinity and 
specificity [24]. As mouse antibody can elicit 
detrimental immunogenic responses in humans 
due to the human anti-mouse antibody reaction, 
humanization of Lic5, which is a mouse 
monoclonal antibody, is a prerequisite if we plan 
to use this antibody in humans in the future. With 
our identified CDRs on Lic5, next phase will 
involve generation of humanized Lic5 by grafting 
the identified CDRs and related amino acid 
sequence to a human antibody framework. The 
methodology for antibody humanization has 
evolved throughout these decades and a number 
of traditional and updated methods are 
developed for antibody humanization [25]. All 
these methods serve the same purpose by 
removing as much mouse sequences on 
antibody as possible, while at the same time 
retaining the essential CDR sequences. Other 
properties including stability and 
pharmacokinetics also need careful optimization 
during the process of antibody humanization [26]. 
For Lic5 with proven anti-tumor and 
chemosensitizing effects, we will perform 
antibody humanization. Upon completion, 
humanized Lic5 will then undergo extensive and 
vigorous testing before it can be considered for 
use in humans.   
 
5. CONCLUSION 
 
This paper examines the potential use of a 
monoclonal antibody Lic5 in treating HCC 
xenografts in nude mice. Results derived from 
this study have validated the preclinical use of 
Lic5 and envisioned the potential use of Lic5 as 
HCC therapy.  
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